BridgeMD
KetCRPS-2
EU CTIS ID: 2024-511877-31-00
What this study is testing
The aim of this study is to assess whether a series of esketamine infusions, every 2 weeks for 3 months, in a day treatment setting, is non-inferior at 3 months after the start of the treatment to the standard treatment of a 6-day clinical admission of continuous esketamine administration.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- Meeting the new International Association for the Study of Pain (IASP) diagnostic criteria for CRPS (“the Budapest Criteria) or having met the new IASP diagnostic criteria of CRPS (“CRPS with Remission of Some features”)
- Willing and capable to participate in the study.
- CRPS in one upper extremity and/or CRPS in one lower extremity
- Treatment in an elective setting
- Adequate comprehension of the Dutch language
You likely can't join if
- Contraindications to and precautions for use of subanesthetic doses of ketamine for chronic pain are listed by Cohen et al. and the Dutch CRPS guidelines and our clinical protocol
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.